Abeona closes $25M direct offering; proceeds to fund EB-101 commercialization

ABEONA THERAPEUTICS INC.

Gross proceeds of $25M from sale of 3.28M shares and 2.92M pre-funded warrants at $4.03 per share.
Offering led by Nantahala Capital Management with participation by Adage Capital Partners and other existing investors.
Net proceeds to fund commercialization of EB-101 and extend cash runway into Q4 2024.
Company expects to qualify for a priority review voucher upon potential BLA approval in H1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.